The required shift of a scientific paradigm will not inevitably lead to ignoring amyloid beta peptide as one aspect of AD but, rather, will alleviate the pressure on it being the only possible initial trigger of the disease; amyloid beta peptide may be entering the picture later in the disease process but not at the beginning. This evidence concerns the gene APP and Alzheimer disease.